Michela Boromei - Academia.edu (original) (raw)

Uploads

Papers by Michela Boromei

Research paper thumbnail of Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing

Journal of Clinical Medicine

Parenteral prostanoids are being recommended in pulmonary arterial hypertension (PAH) treatment, ... more Parenteral prostanoids are being recommended in pulmonary arterial hypertension (PAH) treatment, but the prognostic relevance of delayed treatment initiation is still debated. This study assessed the impact of the timing of prostacyclin treatment initiation on reducing PVR and achieving a low-risk profile in PAH patients. The study enrolled 151 patients who started on parenteral prostanoids with different treatment strategies. All patients underwent right heart catheterization, clinical evaluation, and risk assessments at baseline and after 1-year follow-up. Patients with an upfront strategy including parenteral prostanoid plus one oral drug had −5.3 ± 6.2 WU (−50 ± 19%) reduction in PVR, patients with an upfront strategy including parenteral prostanoid plus double oral drug had −12.8 ± 5.9 WU (−68 ± 17%) reduction in PVR, while patients with an add-on strategy including parenteral prostanoid after oral drugs had −3.9 ± 3.5 WU (−23 ± 19%) reduction in PVR. An upfront strategy includ...

Research paper thumbnail of 1143 Impact of Non-Cardiac Comorbidities on Diastolic Properties in Hfref and Hfmref Patients

European Heart Journal Supplements, Dec 14, 2022

Research paper thumbnail of Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing

Journal of Clinical Medicine

Parenteral prostanoids are being recommended in pulmonary arterial hypertension (PAH) treatment, ... more Parenteral prostanoids are being recommended in pulmonary arterial hypertension (PAH) treatment, but the prognostic relevance of delayed treatment initiation is still debated. This study assessed the impact of the timing of prostacyclin treatment initiation on reducing PVR and achieving a low-risk profile in PAH patients. The study enrolled 151 patients who started on parenteral prostanoids with different treatment strategies. All patients underwent right heart catheterization, clinical evaluation, and risk assessments at baseline and after 1-year follow-up. Patients with an upfront strategy including parenteral prostanoid plus one oral drug had −5.3 ± 6.2 WU (−50 ± 19%) reduction in PVR, patients with an upfront strategy including parenteral prostanoid plus double oral drug had −12.8 ± 5.9 WU (−68 ± 17%) reduction in PVR, while patients with an add-on strategy including parenteral prostanoid after oral drugs had −3.9 ± 3.5 WU (−23 ± 19%) reduction in PVR. An upfront strategy includ...

Research paper thumbnail of 1143 Impact of Non-Cardiac Comorbidities on Diastolic Properties in Hfref and Hfmref Patients

European Heart Journal Supplements, Dec 14, 2022

Log In